166 related articles for article (PubMed ID: 33097455)
21. Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study.
Ito T; Sanford D; Tomuleasa C; Hsiao HH; Olivera LJE; Enjeti AK; Conca AG; Del Castillo TB; Girshova L; Martelli MP; Guvenc B; Bui CN; Delgado A; Duan Y; Guijarro BG; Llamas C; Lee JH
Eur J Haematol; 2022 Jul; 109(1):58-68. PubMed ID: 35298049
[TBL] [Abstract][Full Text] [Related]
22. Outcomes and health care utilization of older patients with acute myeloid leukemia.
Sharplin K; Wee LYA; Singhal D; Edwards S; Danner S; Lewis I; Thomas D; Wei A; Yong ASM; Hiwase DK
J Geriatr Oncol; 2021 Mar; 12(2):243-249. PubMed ID: 32713804
[TBL] [Abstract][Full Text] [Related]
23. Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis.
Reljic T; Sehovic M; Lancet J; Kim J; Al Ali N; Djulbegovic B; Extermann M
J Geriatr Oncol; 2020 Nov; 11(8):1293-1308. PubMed ID: 32665186
[TBL] [Abstract][Full Text] [Related]
24. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
[TBL] [Abstract][Full Text] [Related]
25. Determination of fitness and therapeutic options in older patients with acute myeloid leukemia.
Cortes JE; Mehta P
Am J Hematol; 2021 Apr; 96(4):493-507. PubMed ID: 33368536
[TBL] [Abstract][Full Text] [Related]
26. Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study.
Budziszewska BK; Pluta A; Sulek K; Wierzbowska A; Robak T; Giebel S; Holowiecka-Goral A; Sawicki W; Ejduk A; Patkowska E; Manko J; Gajkowska-Kulik J; Piszcz J; Mordak-Domagala M; Madry K; Holowiecki J; Kyrcz-Krzemien S; Nowakowska-Domagala M; Dmoszynska A; Calbecka M; Kloczko J; Wiktor Jędrzejczak W; Lange A; Razny M; Bilinski P; Warzocha K; Lech-Maranda E
Leuk Lymphoma; 2015; 56(8):2331-8. PubMed ID: 25393675
[TBL] [Abstract][Full Text] [Related]
27. Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction.
Rao AV
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):339-347. PubMed ID: 27913500
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.
Gemuenden C; Benz R; Senn O; Goede JS; Manz MG; Gerber B
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):811-5. PubMed ID: 26437871
[TBL] [Abstract][Full Text] [Related]
29. The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study.
Marconi G; Candoni A; Di Nicola R; Sartor C; Parisi S; Abbenante M; Nanni J; Cristiano G; Zannoni L; Lazzarotto D; Giannini B; Baldazzi C; Bandini L; Ottaviani E; Testoni N; Bezzi CDG; Abd-Alatif R; Ciotti G; Fanin R; Martinelli G; Paolini S; Ricci P; Cavo M; Papayannidis C; Curti A
Cancer Med; 2023 May; 12(10):11838-11848. PubMed ID: 36999931
[TBL] [Abstract][Full Text] [Related]
30. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
31. Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review.
Laribi K; Sobh M; Ghez D; Baugier de Materre A
Ann Hematol; 2021 Jun; 100(6):1359-1376. PubMed ID: 33796898
[TBL] [Abstract][Full Text] [Related]
32. A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.
Bell JA; Galaznik A; Farrelly E; Blazer M; Murty S; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV; Kota VK
Leuk Res; 2019 Mar; 78():45-51. PubMed ID: 30716655
[TBL] [Abstract][Full Text] [Related]
33. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
[TBL] [Abstract][Full Text] [Related]
34. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
Gardin C; Chevret S; Pautas C; Turlure P; Raffoux E; Thomas X; Quesnel B; de Revel T; de Botton S; Gachard N; Renneville A; Boissel N; Preudhomme C; Terré C; Fenaux P; Bordessoule D; Celli-Lebras K; Castaigne S; Dombret H
J Clin Oncol; 2013 Jan; 31(3):321-7. PubMed ID: 23248249
[TBL] [Abstract][Full Text] [Related]
35. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
Vachhani P; Al Yacoub R; Miller A; Zhang F; Cronin TL; Ontiveros EP; Thompson JE; Griffiths EA; Wang ES
Leuk Res; 2018 Dec; 75():29-35. PubMed ID: 30445237
[TBL] [Abstract][Full Text] [Related]
36. Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands.
Kalin B; Pijnappel EN; van Gelder M; Visser O; van de Loosdrecht AA; Ossenkoppele GJ; Cornelissen JJ; Dinmohamed AG; Jongen-Lavrencic M
Cancer Epidemiol; 2018 Dec; 57():90-96. PubMed ID: 30347337
[TBL] [Abstract][Full Text] [Related]
37. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD
Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study.
Brandwein JM; Saini L; Geddes MN; Yusuf D; Liu F; Schwann K; Billawala A; Westcott C; Kurniawan JA; Cheung WY
Am J Blood Res; 2020; 10(4):124-133. PubMed ID: 32923092
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status.
Yoon JH; Cho BS; Kim HJ; Kim JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Am J Hematol; 2013 Dec; 88(12):1074-81. PubMed ID: 23983148
[TBL] [Abstract][Full Text] [Related]
40. Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia.
Bhatt VR; Wichman C; Al-Kadhimi ZS; Koll TT; Fisher AL; Mahato RI; Hyde RK; Berger A; Armitage JO; Holstein SA; Maness LJ; Gundabolu K
J Geriatr Oncol; 2022 Jul; 13(6):871-874. PubMed ID: 35450817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
